Harborside and Medicine Man Technologies Add to Board of Directors; Gofire Hires Yale Professor; FSD Pharma Votes in CEO; Elevate CBD Names VP | Career Watch

Career watch Harborside fsd pharma Elevate cbd Gofire mg magazine mgretailer
Career watch Harborside fsd pharma Elevate cbd Gofire mg magazine mgretailer

Following an incredibly complicated reverse takeover, merger, and restructuring, Lineage Grow Company Ltd. and FLRish Inc. have come together to form Harborside Inc.

The process began when Lineage Grow Company Ltd. and FLRish Inc. engineered a reverse takeover; FLRish operated as Harborside, one of the oldest dispensaries, manufacturers, and cultivators in California. The RT was completed by way of a “three-cornered merger,” whereby FLRish merged with Harborside Inc. subsidiary Lineage Merger Sub Inc. to form a merged corporation that will operate as a wholly owned subsidiary of Harborside Inc.


The company’s new board of directors consists of Andrew Berman, Peter Bilodeau, Adam Szweras, Matthew K. Hawkins, Tracy Geldert, Sherri Altshuler, and Nayir Felix Munoz, with Mr. Bilodeau as Chairman. Berman, formerly chief executive officer of FLRish, serves as Harborside Inc.’s president and chairman of the board. FLRish co-founder Steve DeAngelo was named chairman emeritus.

Healthcare technology firm Gofire has hired Oberlin College and Yale University assistant professor Meghan Morean, Ph.D. as director of research and clinical applications. Dr. Morean will lead the company’s research directives.

“Researchers, universities, health care systems, and hospitals are all interested in the clinical applications of plant-based medicines,” said Dr. Morean in a statement. “As this demand increases, Gofire can help bridge the gap between the specifications of any study and the means to achieve investigators’ research goals. Given my background, I’m very familiar with conducting research including clinical trials. This is a comfortable space for me, so I can speak both the language of the researcher and the technology of Gofire.”

“Gofire has been steadily working toward the day when physicians can confidently prescribe plant-based medicines and patients can comfortably accept these recommendations to easily gain relief from their ailments,” said Chief Executive Officer Peter Calfee. “It’s why one of our core missions is to help enable researchers to gather the data they need to make that day a reality. We’re excited to welcome Meghan to the Gofire family and look forward to introducing her to our research partners and colleagues pursuing these goals.”

Medicine Man Technologies, Inc., a vertically integrated cannabis operator, has entered into binding term sheets to acquire the assets and rights from Colorado-based Los Sueños Farms LLC., Mesa Organics Ltd. (d/b/a Purplebee’s), Mesa Organics II Ltd., and Mesa Organics III Ltd. (collectively “MesaPur”). Under Colorado law, these sales cannot be completed until after November 1, when House Bill 1090 goes into effect, because MMT is a publicly held company.

The term sheet with MesaPur provides for the appointment of Los Sueños founder Bob DeGabrielle to the board of Medicine Man Technologies. Prior to owning the largest recreational cannabis cultivation facility in the country, DeGabrielle was an early investor in the cannabis space and, along with his partners, invested $10 million in Colorado’s tightly regulated industry.

MMT plans to finish purchasing Los Sueños and MesaPur by February 1, 2020.

Dr. Raza Bokhari

FSD Pharma Inc.’s board of directors has unanimously voted Executive Co-Chairman of the Board Raza Bokhari, M.D. permanent chief executive officer. Dr. Bokhari has served as interim chief executive officer since February.

“It is a high honor to assume such an awesome responsibility at this very important inflection point in our company’s history,” said Dr. Bokhari. “I am counting on our hardworking and enterprising team, our esteemed board members, and the generous support of our shareholders and stakeholders to guide me in my role as CEO.”

FSD founder and Executive Co-Chairman Anthony Durkacz said, “As interim CEO, Dr. Bokhari has already navigated the company through some tough decisions, and he is rapidly advancing our strategic vision and mission to become a market leader in medicinal cannabis and cannabinoid pharmaceutical applications. It was a logical and easy decision for the board to unanimously appoint Dr. Bokhari permanent CEO in addition to his role as the executive co-chairman. I have no doubt in my mind that he will lead FSD to better days ahead.”

Cindy Blum

Axcentria Pharmaceutical, the parent company of Elevate CBD, has named Cindy Blum vice president of marketing. Blum will be responsible for leading Elevate CBD’s branding and marketing initiatives.

“Cindy has a consumer-first approach, and a proven track record of defining brand visions and integrated marketing plans that drive increased brand share,” said Paul Litwack chief executive officer at Axcentria Pharmaceuticals. “Her collaborative work ethos is a natural fit for Elevate CBD’s pharmaceutically produced, ever-expanding line of wellness products.”

“Leading marketing and innovation for Elevate CBD is incredibly exciting,” said Blum. “With Axcentria’s pharmaceutical expertise, retailers’ trust in the brand, and a smart marketing approach, the growth potential of this quality-driven brand is limitless. Elevate CBD will help millions of people get back to living through attainable wellness solutions.”

Blum’s previous experience includes serving as senior marketing and innovation manager at PepsiCo, global brand director at Kellogg’s, and senior associate brand and innovation manager at Unilever.